Vijayvergia N, Dotan E, Devarajan K, et al. Patterns of care and outcomes of older versus younger patients with metastatic pancreatic cancer: A Fox Chase Cancer Center Experience. J Geriatr Oncol. 2015; S1879-4068. [Epub ahead of print]. PubMed
Dotan E, Li T, Hall M, Meropol N, Beck R, Wong YN. Oncologists’ Response to New Data Regarding the Use of Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer. JOP. September 2014 10(5): 308-14. PubMed
McCleary N, Dotan E, Browner I. Refining Chemotherapy Approach for Older Patients with Colon Cancer. J Clin Oncol, August 2014; 32: 2570-2580. PubMed
Dotan E, Devarajan K, D’Silva JA, Beck A, Kloth D, Cohen J S, Denlinger C. Patterns of use and tolerance of anti-epidermal growth factor receptor antibodies among older adults with metastatic colorectal cancer. Clinical Colorectal Cancer. September 2014; 13(3):192-8. PubMed
Dotan E, Meropol N, Zhu F, Bove B, Cai K, Godwin A, Golemis A, Astsaturov I, Cohen S. Increased Aurora kinase A gene copy number is associated with improved prognosis and response to chemotherapy in patients with metastatic colorectal cancer. British Journal of Cancer. 2012 Feb 14;106(4):748-55 PubMed
Dotan E, Browner I, Hurria A, Denlinger C: Challenges in the management of elderly patients with colon cancer. JNCCN February 2012, 10(2):213-24 PubMed
Dotan E, Meropol J N, Burtness B, Denlinger C et al. A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as front line therapy for metastatic colorectal cancer. A Fox Chase Extramural Research Study. J Gastrointest Cancer, December 2012, 43(4), 562-569. PMCID: PMC340072 PubMed
Dotan E, Cohen S J. Challenges in the management of stage II colon cancer. Seminars in Oncology Aug 2011; 38(4): 511-20 PubMed
Dotan E, Cohen S J, Alpaugh K, Meropol N J. Circulating tumor cells: evolving evidence and future challenges. The oncologist, November 2009, 14(11): 1070-1082 PubMed
16 PATIENT COMMENTS